Latest Period
Q2 2026
Security Snapshot
Camp4 Therapeutics Corp - Common Stock (CAMP) Institutional Ownership
CUSIP: 13463J101
13F Institutional Holders and Ownership History from Q4 2024 to Q2 2026
Institutions Reporting
16
Shares (Excl. Options)
2,300,368
Price
$4.37
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock
- Symbol
- CAMP on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 2,300,368
- Total 13F value
- $10,052,608
- Portfolio coverage rank
- 0%
- Share change
- +1,569,958
- Value change
- +$6,860,716
- Number of holders
- 16
- Shares outstanding
- 63,772,061
- SEC-reported price per share
- $4.50
- Insider filing price
- $4.50
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- CAMP - Camp4 Therapeutics Corp - Common Stock is tracked under CUSIP 13463J101.
- 16 institutions reported positions in Q2 2026.
- 11 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 46 to 16 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $175,508,361 to $10,052,608.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 16 institutions filings for Q2 2026.
Security key
13463J101
Latest holder period
Q2 2026
13F holders
16
13D/G owners
11
CIK / CUSIP context first
Open Q2 2026 holders
CAMP full holder history
Camp4 Therapeutics Corp SEC filings
Camp4 Therapeutics Corp company facts
Camp4 Therapeutics Corp insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 13463J101:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
11
Security
CAMP
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| 5AM Ventures VI, L.P. | 9.9% | -20% | $28,410,453 | +$1,999,544 | 6,313,434 | +7.6% | Andrew J. Schwab | 03 Aug 2026 |
| JANUS HENDERSON GROUP PLC | 12% | $37,908,892 | 6,307,636 | JANUS HENDERSON GROUP PLC | 31 Dec 2025 | |||
| FMR LLC | 9.5% | +40% | $28,968,451 | +$10,440,496 | 4,918,243 | +56% | FMR LLC | 31 Dec 2025 |
| Coastlands Capital LP | 10% | $21,452,710 | 4,886,722 | Coastlands Capital LP | 10 Sep 2025 | |||
| Polaris Management Co. VII, L.L.C. | 8.4% | $5,623,119 | 3,932,251 | Amir Nashat | 09 Sep 2025 | |||
| Vivo Opportunity Fund Holdings, L.P. | 7.4% | -2.5% | $23,373,365 | +$1,788,900 | 3,856,991 | +8.3% | Vivo Opportunity Fund Holdings, L.P. | 31 Dec 2025 |
| BALYASNY ASSET MANAGEMENT L.P. | 5.1% | $11,819,642 | 2,632,437 | Balyasny Asset Management L.P. | 31 Mar 2026 | |||
| Enavate Sciences GP, LLC | 4.8% | -20% | $10,955,517 | -$2,773,593 | 2,495,562 | -20% | Enavate Sciences GP, LLC | 09 Mar 2026 |
| Northpond Ventures II, LP | 4.8% | $6,714,732 | 2,238,244 | Michael P. Rubin | 30 Sep 2025 | |||
| AH Bio Fund I, L.P. | 4.5% | $6,376,017 | 2,125,339 | Marc L. Andreessen | 30 Sep 2025 | |||
| HARBOURVEST PARTNERS LLC | 2.7% | -60% | $3,536,015 | 1,271,948 | 0% | HarbourVest Partners L.P. | 30 Sep 2025 |
As of 30 Jun 2026, 16 institutional investors reported holding 2,300,368 shares of Camp4 Therapeutics Corp - Common Stock (CAMP). This represents 3.6% of the company’s total 63,772,061 outstanding shares.
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
7
Latest
Q2 2026
Rows shown
1-7 of 7
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 2,300,368 | $10,052,608 | +$6,860,716 | $4.37 | 16 |
| 2026 Q1 | 39,782,653 | $175,508,361 | +$5,383,258 | $4.41 | 46 |
| 2025 Q4 | 38,247,378 | $234,599,194 | +$51,453,984 | $6.13 | 39 |
| 2025 Q3 | 28,210,083 | $84,630,390 | +$49,505,803 | $3.00 | 28 |
| 2025 Q2 | 11,744,129 | $17,029,220 | -$3,217,598 | $1.45 | 28 |
| 2025 Q1 | 12,677,488 | $50,710,355 | -$1,002,366 | $4.00 | 39 |
| 2024 Q4 | 12,854,057 | $67,096,861 | +$47,332,167 | $5.22 | 36 |